Chi Sheng Pharma & Biotech Valuation
Is 4111 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 4111 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 4111 (NT$26.25) is trading above our estimate of fair value (NT$22.81)
Significantly Below Fair Value: 4111 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 4111?
Other financial metrics that can be useful for relative valuation.
| What is 4111's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | NT$1.50b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.2x |
| Enterprise Value/EBITDA | 10.5x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does 4111's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 55.7x | ||
4127 Tien Liang BioTech | 90.2x | n/a | NT$1.6b |
4102 Yung Zip Chemical Ind | 26.9x | n/a | NT$1.7b |
4130 Genovate Biotechnology | 90.6x | n/a | NT$2.7b |
6817 Winston Medical Supply | 15.1x | n/a | NT$2.4b |
4111 Chi Sheng Pharma & Biotech | 21.8x | n/a | NT$1.5b |
Price-To-Earnings vs Peers: 4111 is good value based on its Price-To-Earnings Ratio (21.8x) compared to the peer average (55.7x).
Price to Earnings Ratio vs Industry
How does 4111's PE Ratio compare vs other companies in the TW Pharmaceuticals Industry?
Price-To-Earnings vs Industry: 4111 is good value based on its Price-To-Earnings Ratio (21.8x) compared to the TW Pharmaceuticals industry average (25.9x).
Price to Earnings Ratio vs Fair Ratio
What is 4111's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 21.8x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 4111's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.